Previous 10 | Next 10 |
- PDUFA Goal Date Set for August 1, 2021 - Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin NESS ZIONA, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatolog...
Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug. Two late stage candidates. Funded sufficiently to pull through the anticipated approvals. For further details see: ...
Sol-Gel Technologies (SLGL): Q3 GAAP EPS of -$0.37 beats by $0.09.Revenue of $2.12M (-55.2% Y/Y) beats by $0.3M.Press Release For further details see: Sol-Gel Technologies EPS beats by $0.09, beats on revenue
Epsolay ® PDUFA goal date set for April 26, 2021 Twyneo ® New Drug Application submitted to the U.S. FDA Top-line generic product revenue of $2.1 million in 3Q 2020 In October 2020 , signed an ...
NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, ...
NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for...
The following slide deck was published by Sol-Gel Technologies Ltd. in conjunction with this Read more ...
VBL Therapeutics reports progress for metastatic colorectal cancer trial VBL Therapeutics ( VBLT ) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for...
The FDA accepts Sol-Gel Technologies' (NASDAQ: SLGL ) New Drug Application (NDA) seeking approval of topical cream Epsolay (benzoyl peroxide) for the treatment of inflammatory lesions of rosacea, characterized by redness and often small, red, pus-filled bumps on the f...
The FDA accepts for review Sol-Gel Technologies' (NASDAQ: SLGL ) marketing application seeking approval of Epsolay (benzoyl peroxide) topical cream for the treatment of inflammatory lesions associated with an acne-like skin condition called rosacea . More news on: Sol-Gel Technologies...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved larg...
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...